CD63 and cancer: To analyze whether HepG2/DDP cell-derived exosomes might confer a malignant phenotype on paclitaxel-sensitive cancer cells, exosomes from HepG2 and HepG2/DDP cell were separated with a typical round shape and verified with their corresponding surface markers including CD9, CD63 and CD81.